Daiichi Sankyo Company (4568-TO)

QUOTE AND NEWS
Forbes  Oct 31  Comment 
On Thursday the FDA's Cardiovascular and Renal Drugs Advisory Committee voted 9-1 in favor of approval for Daiichi Sankyo's edoxaban (Savaysa), but the outcome will likely result in a drug that will be on the market but that few physicians will...
FierceBiotech  Oct 30  Comment 
A panel of FDA advisers voted in favor of approving Daiichi Sankyo's irregular heartbeat treatment edoxaban, heralding its ability to break up blood clots and improving the company's odds of finally launching the drug in the U.S.
FierceBiotech  Oct 28  Comment 
Daiichi Sankyo's campaign to win approval for its atrial fibrillation drug edoxaban gained some support from regulators at the FDA who were clearly won over by the efficacy data in the NDA. But the internal review of the drug also includes...
DailyFinance  Sep 29  Comment 
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Ambit...
DailyFinance  Sep 29  Comment 
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Ambit Biosciences...
MarketWatch  Sep 28  Comment 
Japanese pharmaceutical major Daiichi Sankyo Co. is buying the smaller, U.S.-based biopharma concern Ambit Biosciences Corp. for approximately $315 million in cash, the two companies said Sunday in a joint statement. The $15-a-share price...
FierceBiotech  Aug 7  Comment 
Daiichi Sankyo, Japan's second-largest pharma outfit, has agreed to pay up to $650 million to get its hands on some hydrocodone combo medications, striking a deal with Charleston Laboratories with hopes of cashing in on the demand for pain pills.
Forbes  Jul 14  Comment 
Once again the FDA has reached a conclusion that is directly opposed by some of its own scientists.  Last month the FDA affirmed the safety of olmesartan, a popular blood pressure lowering drug (sold as Benicar and other names). But that...
Motley Fool  Jul 7  Comment 
Portola shares flounder despite the company announcing another collaboration with Daiichi Sankyo. Find out what could have upset investors.





You may also be interested in articles related to Daiichi Sankyo Company (4568-TO):
 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki